Latest Administration News

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Bounty Oil & Gas NL has been notified of the refusal of its Joint Venture Applications for the PEP 11 permit, which remains valid for two months. The company is now considering a legal challenge to this decision.

PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.

Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.

ADX Energy has suspended testing at its Welchau-1 gas well in Upper Austria following a landmark Austrian Constitutional Court ruling that repealed a legal provision preventing environmental objections from halting operations. This development introduces regulatory uncertainty amid ongoing evaluation of the well’s potential.

Magnetic Resources NL reported a $4.39 million net cash outflow from operations in Q4 2024 but strengthened its balance sheet with a $9.41 million financing inflow, ending the quarter with $11.6 million in cash.

Basin Energy advances its Scandinavian uranium exploration with new land applications and awaits key sampling results, buoyed by Sweden's move to lift its uranium mining ban.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

Cassius Mining Limited has successfully raised $1 million through a share placement to fund its Soalara project in Madagascar and ongoing litigation in Ghana, signaling a strategic push in key operational areas.

True North Copper Limited (ASX: TNC) has been reinstated to trading following the appointment of voluntary administrators, signaling a critical juncture for the copper miner’s future.